← board
ITRMF
distress 4/10 · elevated risk$0.030%today-97% from 52w high
Revenue
pre-revenue
Liquidity
$11M
Runway
0.6 yrs
Shares 1y
0%
Price & events
-91.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+19.2%
1W
-26.2%
1M
+93.7%
3M
-91.1%
6M
-96.3%
1Y
-97.5%
2Y
-99.8%
5Y
-99.8%
All
Overview
- Market Cap
- $1.38M
- Enterprise Value
- $10.43M
- Volume
- 0
- 52 Week Range
- $0.01 – $1.13
- Total Shares
- 44.66M
- Float Shares
- 52.37M
- Short %
- 5.80%
- % Held by Insiders
- 0.78%
- % Held by Institutions
- 5.86%
- Beta
- 3.74
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2026-03-30withdrawalWithdrew appeal of prior delisting determination; shares will be delisted on April 1, 2026.SEC 8-K
- 2026-03-27trial discontinuedORLYNVAH · Company filed for winding up, discontinuing all operations including commercialization of ORLYNVAHSEC 8-K
- 2025-05-13partnershipORLYNVAH (sulopenem etzadroxil and probenecid) · Amended promissory note with Pfizer extends deferral of $20M milestone payment from Oct 2026 to Oct 2029.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-30HC Wainwright & Co.Buy → Neutral
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.